Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Trump Says Anthropic No Longer Seen as National Security Threat 
WALTHAM, Mass., Feb. 04, 2016 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2015 before the U.S. financial markets open on Wednesday, February 17, 2016. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will present an update on recent developments and discuss the company’s fourth quarter and full year 2015 financial and operating results.
To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on February 17, 2016 through midnight on February 24, 2016. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 44838187.
The call will be webcast with slides and accessible through the Investors section of the company’s website at www.amagpharma.com. The webcast replay will be available from approximately 11:00 a.m. ET on February 17, 2016 through midnight on March 18, 2016.
About AMAG
AMAG Pharmaceuticals uses its business and clinical expertise to develop and commercialize products that provide clear benefits and improve people’s lives. Based in Waltham, MA, AMAG has a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care. AMAG continues to work to expand the impact of these and future products for patients by delivering on its growth strategy, which includes organic growth, as well as the pursuit of products and companies that align with AMAG’s existing therapeutic areas or those that could benefit from its proven core competencies. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals Contact: Maryann Cimino Manager, Corporate Communications & External Affairs 617-498-3375
